|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.64 CNY | +2.01% |
|
-0.21% | -38.99% |
| 05-16 | Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials | MT |
| 04-25 | Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chengdu Olymvax Biopharmaceuticals Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 487.3 million compared to CNY 320.11 million a year ago. Net income was CNY 110.62 million compared to CNY 36.13 million a year ago.
Basic earnings per share from continuing operations was CNY 0.2873 compared to CNY 0.0991 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -38.99% | 539M | |
| +2.97% | 94.74B | |
| -4.08% | 37.28B | |
| -13.26% | 32.68B | |
| +73.70% | 27.72B | |
| -11.58% | 16.19B | |
| -1.66% | 13.88B | |
| -11.67% | 11.58B | |
| +190.36% | 10.92B | |
| -52.61% | 9.54B |
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. 
